QIAGEN N.V. (QGEN)

NL0015001WM6 - Common Stock

42.99  +0.24 (+0.56%)

After market: 42.99 0 (0%)

Fundamental Rating

6

Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 58 industry peers in the Life Sciences Tools & Services industry. While QGEN has a great profitability rating, there are some minor concerns on its financial health. QGEN has a correct valuation and a medium growth rate.



7

1. Profitability

1.1 Basic Checks

QGEN had positive earnings in the past year.
QGEN had a positive operating cash flow in the past year.
QGEN had positive earnings in 4 of the past 5 years.
Each year in the past 5 years QGEN had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of 5.58%, QGEN is in the better half of the industry, outperforming 79.31% of the companies in the same industry.
QGEN has a better Return On Equity (8.96%) than 79.31% of its industry peers.
QGEN has a better Return On Invested Capital (7.16%) than 79.31% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for QGEN is in line with the industry average of 10.07%.
Industry RankSector Rank
ROA 5.58%
ROE 8.96%
ROIC 7.16%
ROA(3y)6.88%
ROA(5y)5.2%
ROE(3y)12.58%
ROE(5y)9.79%
ROIC(3y)9.15%
ROIC(5y)8.32%

1.3 Margins

QGEN has a better Profit Margin (17.36%) than 87.93% of its industry peers.
In the last couple of years the Profit Margin of QGEN has grown nicely.
QGEN has a Operating Margin of 22.65%. This is amongst the best in the industry. QGEN outperforms 91.38% of its industry peers.
QGEN's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 62.78%, QGEN belongs to the top of the industry, outperforming 89.66% of the companies in the same industry.
In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
Industry RankSector Rank
OM 22.65%
PM (TTM) 17.36%
GM 62.78%
OM growth 3Y-7.62%
OM growth 5Y2.99%
PM growth 3Y-3.3%
PM growth 5Y6.5%
GM growth 3Y-1.61%
GM growth 5Y-1.22%

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), QGEN is creating some value.
The number of shares outstanding for QGEN has been reduced compared to 1 year ago.
QGEN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for QGEN has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 3.79 indicates that QGEN is not in any danger for bankruptcy at the moment.
The Altman-Z score of QGEN (3.79) is better than 63.79% of its industry peers.
QGEN has a debt to FCF ratio of 5.09. This is a neutral value as QGEN would need 5.09 years to pay back of all of its debts.
The Debt to FCF ratio of QGEN (5.09) is better than 79.31% of its industry peers.
QGEN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
QGEN's Debt to Equity ratio of 0.24 is in line compared to the rest of the industry. QGEN outperforms 48.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 5.09
Altman-Z 3.79
ROIC/WACC0.87
WACC8.27%

2.3 Liquidity

A Current Ratio of 1.99 indicates that QGEN should not have too much problems paying its short term obligations.
QGEN has a Current ratio of 1.99. This is in the lower half of the industry: QGEN underperforms 65.52% of its industry peers.
QGEN has a Quick Ratio of 1.62. This is a normal value and indicates that QGEN is financially healthy and should not expect problems in meeting its short term obligations.
QGEN's Quick ratio of 1.62 is on the low side compared to the rest of the industry. QGEN is outperformed by 63.79% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.62

4

3. Growth

3.1 Past

The earnings per share for QGEN have decreased strongly by -10.68% in the last year.
The Earnings Per Share has been growing by 9.58% on average over the past years. This is quite good.
The Revenue has decreased by -8.23% in the past year.
Measured over the past years, QGEN shows a small growth in Revenue. The Revenue has been growing by 5.53% on average per year.
EPS 1Y (TTM)-10.68%
EPS 3Y-0.51%
EPS 5Y9.58%
EPS growth Q2Q3.77%
Revenue 1Y (TTM)-8.23%
Revenue growth 3Y1.67%
Revenue growth 5Y5.53%
Revenue growth Q2Q2.24%

3.2 Future

Based on estimates for the next years, QGEN will show a small growth in Earnings Per Share. The EPS will grow by 6.85% on average per year.
Based on estimates for the next years, QGEN will show a quite strong growth in Revenue. The Revenue will grow by 9.63% on average per year.
EPS Next Y1.84%
EPS Next 2Y5.3%
EPS Next 3Y6.73%
EPS Next 5Y6.85%
Revenue Next Year2.65%
Revenue Next 2Y4.62%
Revenue Next 3Y5.33%
Revenue Next 5Y9.63%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 20.28, QGEN is valued on the expensive side.
Based on the Price/Earnings ratio, QGEN is valued cheaper than 98.28% of the companies in the same industry.
When comparing the Price/Earnings ratio of QGEN to the average of the S&P500 Index (26.42), we can say QGEN is valued slightly cheaper.
With a Price/Forward Earnings ratio of 19.94, QGEN is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 96.55% of the companies listed in the same industry.
QGEN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.74, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 20.28
Fwd PE 19.94

4.2 Price Multiples

96.55% of the companies in the same industry are more expensive than QGEN, based on the Enterprise Value to EBITDA ratio.
82.76% of the companies in the same industry are more expensive than QGEN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 32.08
EV/EBITDA 14.64

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)11.01
PEG (5Y)2.12
EPS Next 2Y5.3%
EPS Next 3Y6.73%

3

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 3.01%, QGEN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 0.63, QGEN pays a better dividend. On top of this QGEN pays more dividend than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.34, QGEN pays a bit more dividend than the S&P500 average.
Industry RankSector Rank
Dividend Yield 3.01%

5.2 History

QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y5.3%
EPS Next 3Y6.73%

QIAGEN N.V.

NYSE:QGEN (3/28/2024, 4:10:03 PM)

After market: 42.99 0 (0%)

42.99

+0.24 (+0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap9.52B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 3.01%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 20.28
Fwd PE 19.94
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)11.01
PEG (5Y)2.12
Profitability
Industry RankSector Rank
ROA 5.58%
ROE 8.96%
ROCE
ROIC
ROICexc
ROICexgc
OM 22.65%
PM (TTM) 17.36%
GM 62.78%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.99
Quick Ratio 1.62
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-10.68%
EPS 3Y-0.51%
EPS 5Y
EPS growth Q2Q
EPS Next Y1.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.23%
Revenue growth 3Y1.67%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y